Biocytogen
Biocytogen is a biotechnology company committed to the discovery of antibody-based drugs with global partners. Biocytogen’s Project Integrum aims to discover fully human antibody-based drugs for 1000+ targets using its proprietary RenMab-based platforms. It has resulted in hits against 700+ targets, 50 asset partnerships and 42 RenMice licensing projects. Biocytogen also provides custom and off-the-shelf animal models, and preclinical research services for the discovery and evaluation of novel antibodies, ADCs, cell therapies, etc. Headquartered in Beijing, Biocytogen has branches worldwide.”
